Levomilnacipran

Drug Profile

Levomilnacipran

Alternative Names: 1S, 2R-milnacipran; F 2695; F2695 SR; Fetzima; Levomilnacipran SR

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Pierre Fabre
  • Developer Allergan; Pierre Fabre
  • Class Amides; Amines; Antidepressants; Cyclopropanes; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Major depressive disorder
  • Phase III Stroke
  • No development reported Pain

Most Recent Events

  • 01 Jun 2015 Forest Laboratories initiates enrolment in a phase III trial in Major depressive disorder (In adolescents) in USA (NCT02431806)
  • 14 May 2015 Phase-III development for Major depressive disorder is ongoing in Canada
  • 06 May 2015 Forest Laboratories plans a phase III trial in Major depressive disorder (In adolescents) in USA (NCT02431806)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top